Maze Therapeutics (NASDAQ:MAZE) Issues Earnings Results

Maze Therapeutics (NASDAQ:MAZE) posted its earnings results on Tuesday. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02), FiscalAI reports. The business had revenue of $20.00 million during the quarter.

Maze Therapeutics Stock Performance

MAZE opened at $25.78 on Wednesday. The business has a 50 day moving average price of $34.56 and a 200 day moving average price of $38.06. The firm has a market cap of $1.28 billion, a P/E ratio of -7.98 and a beta of 2.50. Maze Therapeutics has a twelve month low of $8.24 and a twelve month high of $53.65.

Insiders Place Their Bets

In other Maze Therapeutics news, SVP Amy Bachrodt sold 2,500 shares of Maze Therapeutics stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $29.44, for a total value of $73,600.00. Following the transaction, the senior vice president directly owned 12,965 shares of the company’s stock, valued at $381,689.60. The trade was a 16.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $25.37, for a total value of $190,275.00. Following the completion of the transaction, the insider directly owned 10,503 shares in the company, valued at approximately $266,461.11. This represents a 41.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 70,000 shares of company stock valued at $2,955,775 in the last three months. Company insiders own 5.30% of the company’s stock.

Institutional Trading of Maze Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada increased its position in shares of Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Maze Therapeutics in the 4th quarter valued at $39,000. Caitong International Asset Management Co. Ltd acquired a new stake in Maze Therapeutics in the 4th quarter valued at $43,000. California State Teachers Retirement System boosted its stake in Maze Therapeutics by 138.0% in the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after buying an additional 766 shares in the last quarter. Finally, Ameritas Investment Partners Inc. boosted its stake in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts have issued reports on MAZE shares. BTIG Research reiterated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday, March 25th. HC Wainwright lifted their target price on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, March 25th. Truist Financial dropped their price target on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, April 14th. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Finally, Mizuho upgraded Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.